Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
Vanderbilt Hereditary Colorectal Cancer Registry
Status: Enrolling
Updated:  8/1/2017
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
Vanderbilt Hereditary Colorectal Cancer Registry
Status: Enrolling
Updated: 8/1/2017
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Click here to add this to my saved trials
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
Vanderbilt Hereditary Colorectal Cancer Registry
Status: Enrolling
Updated:  8/1/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
Vanderbilt Hereditary Colorectal Cancer Registry
Status: Enrolling
Updated: 8/1/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Strategies to Promote Skin Health
Strategies to Promote Skin Health
Status: Enrolling
Updated:  8/1/2017
San Diego State University
mi
from
San Diego, CA
Strategies to Promote Skin Health
Strategies to Promote Skin Health
Status: Enrolling
Updated: 8/1/2017
San Diego State University
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions
A Randomized Trial Evaluating the Number of Passes Required for Diagnostic Cell Block During Endoscopic Ultrasound-Fine Needle Aspiration of Solid Pancreatic Mass Lesions
Status: Enrolling
Updated:  8/2/2017
Florida Hospital
mi
from
Orlando, FL
Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions
A Randomized Trial Evaluating the Number of Passes Required for Diagnostic Cell Block During Endoscopic Ultrasound-Fine Needle Aspiration of Solid Pancreatic Mass Lesions
Status: Enrolling
Updated: 8/2/2017
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm
Randomized Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm
Status: Enrolling
Updated:  8/2/2017
Florida Hospital
mi
from
Orlando, FL
Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm
Randomized Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm
Status: Enrolling
Updated: 8/2/2017
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
Johns Hopkins Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
Johns Hopkins Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
Moffitt Cancer Center
mi
from
Tampa, FL
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum
Status: Enrolling
Updated:  8/3/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum
Status: Enrolling
Updated: 8/3/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer
Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer
Status: Enrolling
Updated:  8/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer
Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer
Status: Enrolling
Updated: 8/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
An Educational Intervention for Patients With Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
Status: Enrolling
Updated:  8/3/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
An Educational Intervention for Patients With Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
Status: Enrolling
Updated: 8/3/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
An Educational Intervention for Patients With Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
Status: Enrolling
Updated:  8/3/2017
James J. Peters VA Medical Center
mi
from
The Bronx, NY
An Educational Intervention for Patients With Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
Status: Enrolling
Updated: 8/3/2017
James J. Peters VA Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Maryland
mi
from
Baltimore, MD
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Institute of Oncology Hematology Biomedical Research LLC
mi
from
Laredo, TX
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Institute of Oncology Hematology Biomedical Research LLC
mi
from
Laredo, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University Health Network
mi
from
Toronto,
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University Health Network
mi
from
Toronto,
Click here to add this to my saved trials
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
Laboratory Studies in Hormone Refractory Prostate Cancer - A Companion Study to CALGB 9480 and 9583
Status: Enrolling
Updated:  8/7/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
Laboratory Studies in Hormone Refractory Prostate Cancer - A Companion Study to CALGB 9480 and 9583
Status: Enrolling
Updated: 8/7/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study
Status: Enrolling
Updated:  8/7/2017
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study
Status: Enrolling
Updated: 8/7/2017
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study
Status: Enrolling
Updated:  8/7/2017
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study
Status: Enrolling
Updated: 8/7/2017
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Click here to add this to my saved trials
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study
Status: Enrolling
Updated:  8/7/2017
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study
Status: Enrolling
Updated: 8/7/2017
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  8/7/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 8/7/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  8/7/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 8/7/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  8/7/2017
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 8/7/2017
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Tumor Samples From Patients With Lung Cancer
A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens
Status: Enrolling
Updated:  8/7/2017
University of Chicago
mi
from
Boston, MA
Study of Tumor Samples From Patients With Lung Cancer
A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens
Status: Enrolling
Updated: 8/7/2017
University of Chicago
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Camino Medical Group - Treatment Center
mi
from
Mountain View, CA
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Camino Medical Group - Treatment Center
mi
from
Mountain View, CA
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Clinical Research Facility
mi
from
Pismo Beach, CA
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Clinical Research Facility
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Bendheim Cancer Center at Greenwich Hospital
mi
from
Greenwich, CT
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Bendheim Cancer Center at Greenwich Hospital
mi
from
Greenwich, CT
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Cancer Center of South Florida Foundation, Incorporated
mi
from
Lake Worth, FL
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Cancer Center of South Florida Foundation, Incorporated
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
La Grange Memorial Hospital
mi
from
La Grange, IL
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
La Grange Memorial Hospital
mi
from
La Grange, IL
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Center for Cancer Care at OSF Saint Anthony Medical Center
mi
from
Rockford, IL
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Center for Cancer Care at OSF Saint Anthony Medical Center
mi
from
Rockford, IL
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Howard Community Hospital
mi
from
Kokomo, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Howard Community Hospital
mi
from
Kokomo, IN
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Center for Cancer Therapy at LaPorte Hospital and Health Services
mi
from
La Porte, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Center for Cancer Therapy at LaPorte Hospital and Health Services
mi
from
La Porte, IN
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Suniti Medical Corporation
mi
from
Merrillville, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Suniti Medical Corporation
mi
from
Merrillville, IN
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Michiana Hematology-Oncology, PC - South Bend
mi
from
Mishawaka, IN
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Michiana Hematology-Oncology, PC - South Bend
mi
from
Mishawaka, IN
Click here to add this to my saved trials